Sanofi is a healthcare company that provides treatments and the protection of life-saving vaccines.
Sanofi offers research, development, manufacturing, and marketing of innovative therapeutic solutions. It covers areas such as diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health, and the new G enzyme. Its products include prescriptions and over-the-counter drugs for thrombosis, cardiovascular disease, diabetes, central nervous system disorders, oncology and internal medicine, vaccines, and other medical products. The two young groups Sanofi and Synthélabo merged in May 1999 to create a major new pharmaceutical player. Sanofi dates back to 1973 and Synthélabo to 1970. In December 1999, Rhône-Poulenc and Hoechst Marion Roussel formalized their merger with the creation of the Franco-German group Aventis, one of the world’s largest pharmaceutical companies. In August 2004, Sanofi-Synthelabo acquired Aventis. The takeover was finalized on December 31 of that year, giving birth to sanofi-aventis.On May 6, 2011, sanofi-aventis simplified its name to Sanofi. Sanofi operates in over 100 countries throughout the world.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 15, 2022 | Post-IPO Equity | €300M | 1 | Blackstone Life Sciences | — | Detail |
Dec 2, 2014 | Post-IPO Equity | $310M | 1 | Evotec | — | Detail |
Jul 12, 2002 | IPO | — | — | — | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Nov 23, 2022
Livmed's
|
Seed | €5M | Delivery Service | Yes |
Aug 4, 2022
Innovent Biologics
|
Post-IPO Equity | $2.42B | Biopharma | Yes |
Jul 12, 2022
Areteia Therapeutics
|
Series A | $350M | Biotechnology | — |
Jan 10, 2022
Exscientia
|
Post-IPO Equity | $100M | Artificial Intelligence | Yes |
Nov 18, 2021
Owkin
|
Corporate Round | $180M | Artificial Intelligence | Yes |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Blackstone Life Sciences | Yes | Post-IPO Equity |
Evotec | Yes | Post-IPO Equity |
Sanofi has had 12 exits. Sanofi most notable exits include Gyroscope Therapeutics , Exscientia
Date | Company Name | Exit Type | Industry | |
---|---|---|---|---|
Dec 22, 2021 | Gyroscope Therapeutics | M&A | Biotechnology | Detail |
Oct 1, 2021 | Exscientia | IPO | Artificial Intelligence | Detail |
Jul 29, 2021 | Icosavax | IPO | Biotechnology | Detail |
Oct 9, 2019 | BioNTech | IPO | Biopharma | Detail |
Jul 17, 2019 | Fulcrum Therapeutics | IPO | Biotechnology | Detail |
Sanofi has acquired 25 organizations. Their most recent acquisition was Aventis SA on Aug 30, 2004. They acquired Aventis SA for 0.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
Aug 30, 2004
Aventis SA
|
Biotechnology | acquisition | — | Detail |
Sep 24, 2008
Zentiva
|
Health Care | acquisition | $ 2.60B | Detail |
Apr 8, 2009
Medley Farma
|
Pharmaceutical | acquisition | — | Detail |
Apr 15, 2009
BiPar Sciences
|
Biotechnology | acquisition | $ 500M | Detail |
Jul 13, 2009
Merial Limited
|
Biotechnology | — | — | Detail |